TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer - PubMed (original) (raw)

TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer

Scott A Tomlins et al. Cancer Res. 2006.

Abstract

Although common in hematologic and mesenchymal malignancies, recurrent gene fusions have not been well characterized in epithelial carcinomas. Recently, using a novel bioinformatic approach, we identified recurrent gene fusions between TMPRSS2 and the ETS family members ERG or ETV1 in the majority of prostate cancers. Here, we interrogated the expression of all ETS family members in prostate cancer profiling studies and identified marked overexpression of ETV4 in 2 of 98 cases. In one such case, we confirmed the overexpression of ETV4 using quantitative PCR, and by rapid amplification of cDNA ends, quantitative PCR, and fluorescence in situ hybridization, we show that the TMPRSS2 (21q22) and ETV4 (17q21) loci are fused in this case. This result defines a third molecular subtype of prostate cancer and supports the hypothesis that dysregulation of ETS family members through fusions with TMRPSS2 may be an initiating event in prostate cancer development.

PubMed Disclaimer

Cited by

Clinical Applications of Molecular Biomarkers in Prostate Cancer.
Couñago F, López-Campos F, Díaz-Gavela AA, Almagro E, Fenández-Pascual E, Henríquez I, Lozano R, Linares Espinós E, Gómez-Iturriaga A, de Velasco G, Quintana Franco LM, Rodríguez-Melcón I, López-Torrecilla J, Spratt DE, Guerrero LL, Martínez-Salamanca JI, Del Cerro E. Couñago F, et al. Cancers (Basel). 2020 Jun 12;12(6):1550. doi: 10.3390/cancers12061550. Cancers (Basel). 2020. PMID: 32545454 Free PMC article. Review.
The biology of castration-resistant prostate cancer.
Lian F, Sharma NV, Moran JD, Moreno CS. Lian F, et al. Curr Probl Cancer. 2015 Jan-Feb;39(1):17-28. doi: 10.1016/j.currproblcancer.2014.11.004. Epub 2014 Nov 25. Curr Probl Cancer. 2015. PMID: 25547388 Free PMC article. Review. No abstract available.
Race and prostate cancer: genomic landscape.
Arenas-Gallo C, Owiredu J, Weinstein I, Lewicki P, Basourakos SP, Vince R Jr, Al Hussein Al Awamlh B, Schumacher FR, Spratt DE, Barbieri CE, Shoag JE. Arenas-Gallo C, et al. Nat Rev Urol. 2022 Sep;19(9):547-561. doi: 10.1038/s41585-022-00622-0. Epub 2022 Aug 9. Nat Rev Urol. 2022. PMID: 35945369 Review.
Therapeutic targeting of SPINK1-positive prostate cancer.
Ateeq B, Tomlins SA, Laxman B, Asangani IA, Cao Q, Cao X, Li Y, Wang X, Feng FY, Pienta KJ, Varambally S, Chinnaiyan AM. Ateeq B, et al. Sci Transl Med. 2011 Mar 2;3(72):72ra17. doi: 10.1126/scitranslmed.3001498. Sci Transl Med. 2011. PMID: 21368222 Free PMC article.
Microsatellites as EWS/FLI response elements in Ewing's sarcoma.
Gangwal K, Sankar S, Hollenhorst PC, Kinsey M, Haroldsen SC, Shah AA, Boucher KM, Watkins WS, Jorde LB, Graves BJ, Lessnick SL. Gangwal K, et al. Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10149-54. doi: 10.1073/pnas.0801073105. Epub 2008 Jul 14. Proc Natl Acad Sci U S A. 2008. PMID: 18626011 Free PMC article.

TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer - PubMed (original) (raw)